• Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24.
• Growth over the financial year was driven by increased sales in oncology, particularly in the United States.
• Several partnership agreements in oncology and neurology strengthen the Group’s R&D portfolio in rare diseases.
• Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group’s ambitions for 2030.

SURESNES, France, Jan. 27, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, published its financial results for the 2024/25 financial year today and recapped the highlights that led to such significant growth.

Olivier Laureau, President of Servier, said: “The solid results from our 2024/25 financial year put us one important step closer to achieving our 2030 objectives. They validate the relevance of our differentiated innovation strategy to serve patients and the commitment of our employees. These results also underscore the success of the Group’s transformation, which began 10 years ago, involving significant investments in innovation and international expansion. Our long-term vision is made possible by the fact that we are governed by a foundation.”

Excerpt from the Group’s audited results^[1] (financial year ending September 30, 2025)

In the 2024/25 financial year, Group revenue reached €6.9 billion, exceeding the €6 billion target. This 16.2% increase over the previous year reflects the Group’s growth momentum and ability to provide patients with an ever-increasing number of medicines.

Revenue growth resulted from a 16.9% increase in sales volume, or €1 billion, compared to 12.6% for FY 2023/24. There was also an unfavorable currency effect of 2.0%, equivalent to €118 million, (compared with an unfavorable impact of 3.5% in the previous year), as well as a positive price effect of 1.3%, equal to €76 million (compared with 1.7% for the 2023/24 financial year).

EBITDA^[2] for the 2024/25 financial year amounted to €1.9 billion, corresponding to a 28.2% revenue margin compared to 22.2% in 2023/24. This increase was driven by significant growth in medicine sales during the financial year, particularly in oncology, combined with effective cost control across the Group. By 2023/24, the Group had already exceeded its 2024/25 target of achieving a 21.7% EBITDA margin.

Consistent with strategy, Servier remains confident in its ability to achieve global annual revenues of €10 billion by 2030 and an EBITDA margin of at least 30%.

Growth fueled by oncology performance in the United States

The 2024/25 financial year was highlighted by several advances in oncology and partnership agreements signed, reflecting the Group’s dedication to developing new therapeutic solutions for patients with rare cancers. In line with the Group’s strategy, oncology continues to grow and now accounts for 32.2% of Group revenue, compared with 24.2% in 2023/24. Oncology revenues amounted to €2.21 billion in 2024-25, an increase of 54.6%. This growth stems from a significant increase in oncology sales volume following the launch of Voranigo® in the United States.

Medicine sales in cardiometabolism and venous diseases underscore the Group’s historic, ongoing commitment in this area. As a result, sales rose by 1.8% to €2.968 billion, boosted by strong sales performance for Daflon^® in venous diseases.

European Union revenues account for 40.5% of Group revenue and show a 9.2% increase over the previous financial year. The US subsidiary remained the Group’s leading operating unit, with revenues of €1.496 billion in 2024/25, compared with €879 million in 2023/24, reflecting growth of 70.3%. The US market generated 21.8% of Group revenue.

Pascal Lemaire, Executive Vice President Finance at Servier, said: “The Group’s 2024/25 financial year results mirror our successful international growth, particularly our oncology business in the United States. They reward the risks taken as part of our targeted strategy and our policy of investing in R&D in rare diseases in oncology and in neurology where there are unmet patient needs. Our results are also a testament to Servier’s decision to raise its growth targets for 2030, particularly to reach €10 billion in revenue.”

Targeted, collaborative R&D to enhance and strengthen the pipeline

In 2024/25, the innovation strategy focused on renewing and sustaining our research and development pipeline through both internal and external growth.

Incorporating AI (artificial intelligence) and data throughout the medicine development chain has now become part of Servier’s ambition to improve R&D productivity to serve patients. AI helps researchers navigate biological complexity and speed up the development of treatments for the right patient at the right time, particularly in rare diseases in oncology and neurology.

Targeted innovation driving growth in oncology

The 2024/25 financial year was once again noteworthy for several marketing authorizations in oncology around the world, bolstering the Group’s ability to develop new therapeutic solutions for rare forms of cancer with unmet medical needs, and get them to patients.

Following approvals in the United States, Australia, Japan, and Brazil, Voranigo^® has now been approved in Europe, bringing the total number of countries to nearly 45. Used to treat patients with a rare form of brain cancer, Voranigo^® is currently administered to more than 5,500 patients in the United States and around the world through early access programs. Alongside this, Tibsovo^®, a targeted therapy in hematology, has been approved for marketing in Japan.

In addition, the Group has finalized three significant partnership agreements that demonstrate its focus on advancing targeted oncology therapies and the value creation potential of its R&D. The Group entered into a licensing agreement with Black Diamond Therapeutics to develop and commercialize a targeted therapy for solid tumors, including non-small cell lung cancer. Additionally, the acquisition of a precision therapy from Chinese biopharmaceutical company BioNova Pharmaceuticals Ltd also enabled the Group build on its leadership in acute leukemia. And finally, Servier joined forces with IDEAYA Biosciences to make Darovasertib available to patients. This is a potential treatment for uveal melanoma, which is a rare type of eye cancer.

Featuring in the Top 10 of the PatientView Survey^[3] and obtaining the leading position in the oncology category are recognition of the Group’s unwavering dedication to patients and patient advocacy groups.

Aspiring to be a leading force in neurology

Building on its ongoing transformation, the Group aims to establish a leading neurology franchise by developing a robust pipeline in rare neurological diseases modeled on its oncology strategy. Servier is targeting three main types of neurological diseases associated with a genetic and/or immuno-inflammatory mechanism: refractory epilepsy, rare movement disorders, and neuromuscular diseases. Servier R&D is focused on small molecules that target messenger RNA, particularly antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies. To date, the neurology pipeline comprises eight research projects and three projects in development.

Servier has initiated a Phase 1 clinical trial for a product to treat developmental and epileptic encephalopathy (DEE) in children, a rare form of epilepsy that is resistant to conventional anticonvulsant drugs. In the field of DEE, the Group has also partnered with University College London to test ASOs from Servier in innovative cell models, called brain assembloids, which replicate key aspects of human brain development and function.

Leveraging the strength of its global resources, Servier also intends to become a partner of choice for innovative biotech companies in the development of new drugs that slow or halt the progression of rare neurological disorders and significantly improve patient quality of life.

Over the past year, the Group has therefore enriched its pipeline with the acquisition of a first asset in autism spectrum disorder (ASD) from biotech company Kaerus Bioscience Ltd. This asset is a potential treatment for Fragile X syndrome, the most common genetic cause of ASD, for which there are currently no treatment options.

Innovation continues with a focus on improving patient adherence to cardio-metabolic therapies

Servier maintains its position as the world’s leading pharmaceutical company in hypertension[4]. Cardiometabolism and venous diseases accounted for 43.3% of consolidated revenues in FY 2024/25, with performance driven by sales of Daflon^® as well as growth in Single Pill Combinations (SPCs), which make it possible for patients with multiple and chronic conditions to take their various treatments in a single pill.

Several marketing authorization applications were submitted in many countries for an extended-release triple therapy in hypertension and its first quadruple therapy. These innovations are designed to address the issue of treatment non-adherence, a major health challenge for the nearly 50% of patients with chronic diseases who do not follow their prescribed treatment plans exactly[5], which also places a financial burden on health care systems. Among other initiatives, Servier partnered with 14 institutions to sponsor the first World Adherence Day.

Claude Bertrand, Executive Vice President Research and Development at Servier: “Our differentiated approach is paying off. Following major oncology launches in 2025 that consolidate our expertise in rare cancers, we are investing in rare neurological diseases while continuing our innovations in Single Pill Combinations (SPCs) in cardiometabolism. All our R&D projects are clinically grounded and focused on critical unmet medical needs, leveraging recent scientific and technological inflection points. They represent decisive and sustainable choices with one ultimate beneficiary: the patient.”

Last but not least, the creation of Servier’s venture capital fund — Servier Ventures — will also help further the Group’s R&D strategy by strengthening direct, early access to innovation in its target therapeutic areas and fueling the long-term pipeline. Through investment and support for innovative start-ups, this fund gives Servier the opportunity to position itself as a partner of choice within the biotech ecosystem, promoting the development of new and innovative medicines.

Press Contact
presse@servier.com 

About Servier 

Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.

As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D.

Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.

More information on the Group website: servier.com 

Follow us on social media: LinkedIn, Facebook, X, Instagram 

[1] The Group’s 2024/25 financial information is presented on a pro forma basis, comparable to the previous financial year, and includes Biogaran business. Excluded are restatements related to IFRS 5 regarding businesses held for sale.

[2] EBITDA is used as an indicator of operating performance (EBITDA: Earnings before interest, taxes, depreciation, and amortization) based on recurring operating income excluding items such as asset disposals and other non-recurring costs.

[3] PatientView’s Corporate Reputation of Pharma, 2024. The Patient Perspective — Global Edition.

[4]  IQVIA, Analytics Link / World 84 countries – MAT Q3-2025

[5] Adherence to Long-Term Therapies: Evidence for action. World Health Organization, 2003.

 

HONG KONG, Jan. 27, 2026 /PRNewswire/ — Hong Kong’s first CSI A500 Index ETF— CSOP Huatai-PineBridge CSI A500 ETF (Stock Code: 3101.HK), will list on Hong Kong Stock Exchange (HKEX) on January 28, 2026. The listing price for 3101.HK is approximately HKD 7.9 per share, the trading lot size is 100 shares, and the annual management fee is 0.99%.

The listing of CSOP Huatai-PineBridge CSI A500 ETF on HKEX marks the continued opening-up of China’s financial markets and an important step in the internationalization of Chinese assets. 3101.HK is a feeder fund that, to achieve its investment objective, will invest at least 90% of its NAV in the Huatai-PineBridge CSI A500 ETF (the master fund) via the QFI status granted to CSOP Asset Management and/or the Shanghai-Hong Kong Stock Connect. The master fund was listed on Shanghai Stock Exchange in 2024 and, as of January 8, 2026, has approximately RMB 49.5 billion in assets under management, the largest among peer products globally^[1]. The fund features low tracking error, high index replication, and significant scale advantages. Hong Kong investors can trade this ETF on the secondary market in HKD, with a minimum investment of about HKD 790, to capture the long-term growth opportunities of China’s core assets.

The CSI A500 Index (the Index) selects 500 A-share securities with relatively large market capitalization and strong liquidity from across industries as its constituents, aiming to reflect the overall performance of the most representative listed companies in each sector. From an industry allocation perspective, the CSI A500 Index has higher weights in Industrials, Information Technology, Materials, Financials, and Communication Services, which may enhance its potential to deliver relative excess returns. In 2025, CSI A500 Index achieved a return of 22.43%^[2].

Mr. Zhou Yi, CEO of Huatai Securities and Chairman of China Southern Asset Management Co., Ltd. (CSAM) and CSOP Asset Management Limited (CSOP), said: “The listing of CSOP Huatai-PineBridge CSI A500 ETF in Hong Kong is an important step in CSOP’s comprehensive ETF strategy. Leveraging our collaboration with Huatai-PineBridge Investments, this product provides Hong Kong investors with a new channel to invest in leading companies across China’s mainstream industries, helps enrich Hong Kong’s ETF market, and meets investors’ demand for allocating to broad-based A-share indices.”

About CSOP

For over a decade, CSOP has successfully established itself as one of the leading ETF issuers in Hong Kong, with the second largest AUM and demonstrated innovative product development. As of 31 December 2025, the total AUM of CSOP reached 27.4 billion USD by building a healthy ETF ecosystem and managing 64 ETPs and 4 mutual funds in Hong Kong and Singapore markets*. In 2025, 6 out of the top 10 most actively traded ETPs in Hong Kong are managed by CSOP**.

*Source: CSOP
** Source: Bloomberg, from 1 January 2025 to 31 December 2025

Disclaimer and Important Notices

Investment involves risks. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and the full list of risk factors. This material is prepared by CSOP Asset Management Limited and has not been reviewed by the Securities and Futures Commission in Hong Kong. Please read the detailed disclosure and disclaimer carefully by accessing website (https://www.csopasset.com/en/education/disclaimer_en.html).
Issuer: CSOP Asset Management Limited

[1] Source: Shanghai Stock Exchange
[2] Source: China Securities Index Co., Ltd.

SINGAPORE, Jan. 27, 2026 /PRNewswire/ — This Valentine’s Day, make every moment unforgettable with premium valentines flower arrangements from JM Flower. Designed to convey heartfelt affection and timeless romance, the new selection of Valentine’s Day flowers brings beauty, emotion and meaning to one of the most anticipated gifting occasions of the year.

Explore the complete collection of romantic bouquets and floral gifts at: 
https://jm.com.sg/collections/valentines-day-flowers

A Blooming Expression of Love — Curated for Every Romance

Flowers have long been a classic symbol of love, passion and appreciation. In 2026, couples and loved ones are continuing to embrace floral gifts as timeless expressions of affection — with modern twists on tradition including mix-style arrangements, soft palettes, and personalised bouquets that speak directly to the heart.

Whether you prefer classic red roses or contemporary seasonal blooms, JM Flower’s valentines bouquet flowers range offers something for every relationship milestone — from first date celebrations to decades of shared memories.

The Perfect Bouquet for Every Love Story

• Romantic Roses — A favourite choice for Valentine’s Day, roses remain the quintessential valentines flower that never goes out of style.
• Artisan Floral Designs — Hand-crafted Valentine bouquets that blend colour, texture and fragrance for a memorable impression.
• Floral Gifts & Boxes — For those who want flowers paired with thoughtful extras for a complete Valentine’s Day surprise.

Find all these and more in our curated collection at: 
https://jm.com.sg/collections/valentines-day-flowers

Same-Day Delivery & Hassle-Free Shopping

Understanding the busy pace of modern life, JM Flower offers same-day delivery options — ensuring your Valentine’s bouquet flowers arrive fresh, beautiful and right on time. With a seamless online experience and a wide variety of arrangements, you can shop with confidence even at the last minute.

Why Flowers Still Lead the Way in Valentine’s Gifting

Despite evolving gifting trends, flowers continue to be the most impactful way to express love. From the classic red rose to alternative blooms that reflect personality and intention, Valentine’s Day flowers remain unmatched in their emotional resonance.

“Flowers are a universal language of love — they communicate sincerity at a glance,” said a spokesperson for JM Flower.

About JM Flower
JM Flower is a Singapore-based florist specialising in handcrafted floral arrangements and meaningful gift experiences. With a focus on quality, creativity and sentiment, JM Flower delivers memorable bouquets and flower gifts for all life’s special moments.

SANYA, China, Jan. 27, 2026 /PRNewswire/ — Set along the pristine coastline of Hainan, The Sanya EDITION draws inspiration from the vast ocean that surrounds it, striking a refined balance between natural serenity and contemporary energy. From the moment of arrival, the experience is designed to impress: guests pass through lush tropical gardens before arriving at a semi-open lobby, where layered teak wood pavillions, reflective water features and bamboo groves frame uninterrupted views of the South China Sea. A gentle sea breeze carries the signature scent of Le Labo black tea, while impeccably styled hosts move with an effortless rhythm, lending the space an atmosphere reminiscent of a modern runway set within a secluded island retreat.

Driven by a commitment to continual innovation, The Sanya EDITION continues to expand the boundaries of contemporary resort living, contributing to the evolution of Hainan’s and China’s wider vacation market. As one of the largest EDITION hotels worldwide, the property has, since 2019, pioneered large-scale festive seasons and New Year celebrations, later evolving into a comprehensive Chinese New Year program. From the opening of Hainan’s first natural grass tennis court to the debut of the island’s first acrylic tennis court certified with a two-star rating by the International Tennis Federation (ITF); from the early introduction of a destination-style Beach Club to the presentation of Sunset Moment fire dance performances—these first-of-their-kind initiatives continue to set benchmarks for modern luxury resort experiences. Many of these “firsts” found their origin at The Sanya EDITION.

Within these pioneering efforts, sports facilities have become an integral part of the resort’s lifestyle offering. Specially selected for Sanya’s tropical coastal climate, the natural grass tennis courts feature Platinum TE Paspalum grass, combining superior heat tolerance, ecological adaptability, and a fine, uniform texture to deliver a tournament-grade playing experience with elevated sensory refinement. The ITF two-star certified acrylic courts combine professional performance with a contemporary aesthetic, featuring a distinctive palette of pink and sky blue. Pink reflects vitality and innovation, while sky blue echoes the surrounding coastal landscape, allowing sport, design and resort living to seamlessly converge into The Sanya EDITION’s signature Sportcation experience. In addition to tennis, the resort also offers pickleball and padel courts, further enriching its multi-dimensional sports landscape. All courts are equipped with energy-efficient, high-brightness lighting systems, ensuring consistent playing conditions from day to night.

As the Year of the Horse Chinese New Year approaches in 2026, The Sanya EDITION presents a festive season that blends tradition and art, offering a contemporary interpretation of island celebrations. As night falls, a water projection show will unfold above the resort’s unique Private Ocean, where light and water intertwine to create a fully immersive visual experience. On Chinese New Year’s Eve, a luminous Lion Dance performance will take center stage, with glowing silhouettes moving to powerful drumbeats, symbolizing strength and renewal. On the first day of the Chinese New Year, traditional dragon and lion dances will bring vibrant energy to the resort, reimagined within a relaxed island setting.

Festivities continue with the dramatic molten iron fireworks show, as thousands of sparks cascade through the sky like falling stars, illuminating the water below. Drone show will animate the night sky with scenes of New Year blessings, while the “Realm of Light and Silhouettes” aerial performance features phoenix and winged horse soaring overhead—symbols of vitality, prosperity and good fortune for the Year of the Horse. Floating lanterns will drift gently across the water, adding a quiet moment to the celebrations.

Beyond visual spectacle, gastronomy forms a central part of the festive experience. The Sanya EDITION is home to five distinctive restaurants and two bars, led by a creative culinary team offering diverse, all-day dining concepts. The Jade Egret presents modern European cuisine paired with a curated selection of wines and classic cocktails, while Beach Barbacoa blends relaxed seaside dining with bold Indonesian flavors inspired by Jimbaran Bay. Market at EDITION takes inspiration from traditional Chinese warehouses, offering a dynamic mix of local and international cuisines across live cooking stations, including raw bar, bakery, open-fire grill and juice bar. The Sky Bar, perched at the top of the hotel, overlooks the South China Sea, serving as a tranquil poolside retreat by day and a vibrant social lounge by night. On Chinese New Year’s Eve, Xian Hai by the Sea will present a special reunion dinner, featuring a bespoke festive menu crafted from seasonal ingredients.

During the Chinese New Year period, Market at EDITION will offer a themed seafood hotpot dinner buffet from 13 to 23 February 2026, served daily from 5:30 pm to 9:00 pm. The Jade Egret will introduce a series of limited-time menus, including a Valentine’s Day Special Menu on 14 February, a Chinese New Year Special Menu from 16 to 17 February, and a guest chef collaboration from 18 to 19 February with Edorta Lamo, Michelin One Star and Michelin Green Star Chef of Arrea! Restaurant in Spain, presenting an authentic expression of Basque mountain terroir. The Sky Bar will offer both Valentine’s Day and Chinese New Year themed afternoon teas, while Beach Barbacoa at EDITION will feature special menus for both festive occasions.

From illuminated night skies to shimmering waters, from cultural performances to refined culinary experiences, The Sanya EDITION redefines the Chinese New Year through the lens of contemporary resort living—where celebration meets restraint, and tradition unfolds through modern imagination.

Note: Programs are subject to change in accordance with local regulations and weather conditions.

Download link for images:
https://drive.google.com/drive/folders/1ilsrNLVLyoVfN565plBdTlI7F4puv0Pa?usp=sharing

For more information, please visit official website:
https://www.editionhotels.com/sanya/
Instagram: @editionsanya

ABOUT EDITION HOTELS 

EDITION Hotels is an unexpected and refreshing collection of individualized, customized, one-of-a-kind hotels that redefines the codes of traditional luxury. Displaying the best of dining and entertainment, services, and amenities “all under one roof,” each EDITION property is unique, reflecting the best cultural and social milieu of its location and time.

Each hotel, with its individuality, authenticity, originality, and unique ethos, reflects the current spirit and zeitgeist of its location. Although all the hotels look completely different, the brand’s unifying aesthetic is in its approach and attitude to the modern lifestyle rather than its appearance. EDITION is about a mindset and how it makes you feel rather than the way it looks. Sophisticated public spaces, finishes, design, and details serve the experience rather than drive it.

For an underserved market of affluent, culturally savvy, and service-savvy guests, the EDITION experience and lifestyle explores the unprecedented intersection and the perfect balance between taste-making design and innovation and consistent, excellent service globally. EDITION currently operates 20 hotels in New York and Times Square, Miami Beach, West Hollywood, Tampa, Barcelona, Bodrum, London, Reykjavik, Madrid, Rome, Abu Dhabi, Dubai, Sanya China, Shanghai, Tokyo Toranomon, Singapore, Riviera Maya at Kanai, Mexico, a second in Tokyo Ginza, and Jeddah, Saudi Arabia.

Facebook: /EDITIONhotels
Instagram: @EDITIONhotels
editionhotels.com
www.marriott.com